GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » EV-to-EBITDA

Alzinova AB (OSTO:ALZ) EV-to-EBITDA : -2.43 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Alzinova AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alzinova AB's enterprise value is kr39.78 Mil. Alzinova AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr-16.38 Mil. Therefore, Alzinova AB's EV-to-EBITDA for today is -2.43.

The historical rank and industry rank for Alzinova AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ALZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.24   Med: -3.89   Max: -1.76
Current: -2.42

During the past 8 years, the highest EV-to-EBITDA of Alzinova AB was -1.76. The lowest was -7.24. And the median was -3.89.

OSTO:ALZ's EV-to-EBITDA is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 10.33 vs OSTO:ALZ: -2.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Alzinova AB's stock price is kr1.37. Alzinova AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.420. Therefore, Alzinova AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Alzinova AB EV-to-EBITDA Historical Data

The historical data trend for Alzinova AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB EV-to-EBITDA Chart

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -11.35 -10.20 -9.78 -4.48 -6.95

Alzinova AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.48 -5.29 -6.39 -5.72 -6.95

Competitive Comparison of Alzinova AB's EV-to-EBITDA

For the Biotechnology subindustry, Alzinova AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzinova AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzinova AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alzinova AB's EV-to-EBITDA falls into.



Alzinova AB EV-to-EBITDA Calculation

Alzinova AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=39.782/-16.383
=-2.43

Alzinova AB's current Enterprise Value is kr39.78 Mil.
Alzinova AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzinova AB  (OSTO:ALZ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alzinova AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.37/-0.420
=At Loss

Alzinova AB's share price for today is kr1.37.
Alzinova AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.420.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Alzinova AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alzinova AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzinova AB (OSTO:ALZ) Business Description

Traded in Other Exchanges
Address
Pepparedsleden 1, Molndal, SWE, SE-431 83
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB (OSTO:ALZ) Headlines

No Headlines